AbbVie's Upadacitinib Safety Appears Improved In Largest, Longest RA Study
Executive Summary
AbbVie's JAK1 inhibitor upadacitinib bested the company's blockbuster Humira in the largest and longest trial to date – on both efficacy and safety – perhaps alleviating concerns about cardiovascular events.